Voltaren

ApprovedSmall molecule

Novartis

Voltaren is one of 80 small molecule programs targeting Intervertebral Disc Displacement. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intervertebral Disc DisplacementActive, not recruiting

RadiculopathyActive, not recruiting

OsteoarthritisActive, not recruiting

Opioid Use DisorderActive, not recruiting

Intervertebral Disc DisplacementPreclinical

Active, not recruiting

RadiculopathyPhase 3

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

Opioid Use DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

2 2

Cataflam

Bayer Aspirin

Platelet Rich Plasma

25 5

Enbrel

IImmunex

Preclinical

2 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Diclofenac

NCT07145645

Clinical

Trials by Indication[1]

Diclofenac3 trials

Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children

Not yet recruiting·UUniversity of Calgary·Phase 3·NCT07145645·60 enrolled

Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%

Completed·AAkorn, Inc.·Phase 3·NCT02913521·934 enrolled

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets

Completed· Novartis logo

Novartis·Phase 1·NCT00913224·38 enrolled

Osteoarthritis2 trials

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

Completed·GGlenmark Pharmaceuticals Ltd. India·Phase 3·NCT02596451·1,164 enrolled

A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain

Completed·HHALEON·Phase 4·NCT06379893·196 enrolled

Acute1 trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack

Terminated·RR-Pharm·Phase 2·NCT04067492·47 enrolled

Radiculopathy1 trial

Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy

Completed·BBausch Health Americas, Inc.·Phase 3·NCT02508805·100 enrolled

Musculoskeletal Pain1 trial

MuscleCare™ Pain Relief Therapy vs. Voltaren® in the Relief of Trapezius Trigger Point Musculoskeletal Pain.

Completed·UUniversity of Toronto·Phase 4·NCT03939884·120 enrolled

2 more indications

Opioid Use Disorder1 trial

PROUD Study - Preventing Opioid Use Disorders

Terminated·EEmory University·Phase 4·NCT04766996·57 enrolled

Intervertebral Disc Displacement1 trial

Electroacupuncture for Sciatica Due to Intervertebral Disc Displacement

Unknown status·—·N/A·NCT02087462·324 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Voltaren. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Voltaren compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Voltaren. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Voltaren

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Diclofenac3 trials

Osteoarthritis2 trials

Acute1 trial

Radiculopathy1 trial

Musculoskeletal Pain1 trial

Opioid Use Disorder1 trial

Intervertebral Disc Displacement1 trial

References

Drug Info

Quick Facts

Related News